Publications by authors named "Ruth Mayrosh"
Article Synopsis
- In May 2020, the FDA approved rucaparib for adult patients with BRCA mutation-associated metastatic castrate-resistant prostate cancer after treatment with certain therapies, based on promising trial results.
- The trial TRITON2 showed a 44% objective response rate among 62 patients, with many responding for over six months, although safety concerns included a 1.7% death rate from adverse effects.
- Rucaparib's approval marks a significant development for this specific patient group, with ongoing research (TRITON3) aimed at confirming its clinical benefits in treating mCRPC.
